If You Invested in Bora Pharmaceuticls (BORAY)
See the BORAY overviewWhat $1,000 or $10,000 in BORAY Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Aug 20, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $1,025 +3% |
| $10,000 | — | — | — | $10,251 +3% |
Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results. We start BORAY on Aug 20, 2026 because the prices we hold from before that date cannot be compared with the later ones, and a return measured across the two would be wrong.
Custom Calculation
Choose your own date and amount for BORAY$1,000 Investment Over Time
BORAY vs S&P 500Year-by-Year Returns
BORAY annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026Aug 20, 2026 to Oct 1, 2026 | $2.39 | $2.45 | +2.5% | +2.5% |
About Bora Pharmaceuticls
Healthcare · OTC
Bora Pharmaceuticals Co., Ltd. (BORAY) operates as a pharmaceutical manufacturing company and contract development and manufacturing organization serving commercial drug products and pharmaceutical partners. The company is associated with Taiwan-listed shares under 6472.TW and an OTCQX-traded security under BORAY. Its disclosed operations include global commercial manufacturing, development support, and product supply services for established pharmaceutical products.
Bora’s CDMO business includes manufacturing work for pharmaceutical partners across multiple therapeutic areas. At its Mississauga facility, which Bora purchased from GSK in 2020, the company provides end-to-end manufacturing services for commercial product lines and individual products used in areas that include infectious disease, mental health, dermatology, migraine, and other conditions. The company’s manufacturing network also includes an oral solid dose site in Maple Grove, Minnesota, used within its broader pharmaceutical production infrastructure.
Through Upsher-Smith Laboratories, LLC, a Bora subsidiary, the company also participates in the U.S. prescription pharmaceutical market. Upsher-Smith’s activities include launches of generic and branded prescription products, differentiated dosage forms, and patient and healthcare professional support resources tied to specific medicines. Its disclosed products include KYMBEE (deflazacort) Tablets, indicated for Duchenne muscular dystrophy in patients 5 years of age and older, and Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a generic version of Ciprodex.
Bora’s business model combines contract manufacturing services for external pharmaceutical companies with product commercialization through its operating subsidiary. Its disclosures emphasize commercial-scale manufacturing, oral solid dose capabilities, product launches, portfolio diversification, and access-support programs connected to prescribed therapies.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Bora Pharmaceuticls investment returns
How much was $1,000 invested in Bora Pharmaceuticls worth at its last close?
Limited historical data is available for BORAY. The prices we can compare start on 2026-08-20.
Has Bora Pharmaceuticls outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare BORAY performance over available time periods.
For informational and educational purposes only, not investment advice.
